Merck Drops Development Of Obesity Drug Taranabant

October 4, 2008

Merck & Co. has decided to stop the development of their obesity drug taranabant due to side effects realized...Washington (ChattahBox) – Merck & Co. has decided to stop the development of their obesity drug taranabant due to side effects realized.

The drug in question had a lot of promise, and has been in development by Merck & Co. for awhile.

The results of a late-stage clinical study forced them to stop development though, as high doses of the drug caused major side effects.

Side effects included depression, anxiety, suicidal thoughts,

These side effects are simiilar to the other obesity drug in the same class of drugs, Acomplia from Sanofi-Aventis, which has yet to be released in the U.S.


Comments

Got something to say? **Please Note** - Comments may be edited for clarity or obscenity, and all comments are published at the discretion of ChattahBox.com - Comments are the opinions of the individuals leaving them, and not of ChattahBox.com or its partners. - Please do not spam or submit comments that use copyright materials, hearsay or are based on reports where the supposed fact or quote is not a matter of public knowledge are also not permitted.